神经原因性膀胱炎的全球市场 - 2022年～2029年

本报告提供全球神经原因性膀胱炎市场相关调查，提供市场概要，以及各药物类型，各类型，各流通管道，各地区趋势，竞争情形，及加入此市场的主要企业简介等资讯。

目录

第1章 神经原因性膀胱炎市场调查方法与范围

第2章 神经原因性膀胱炎市场-市场定义和概要

第3章 神经原因性膀胱炎市场-摘要整理

• 各药物类型市场明细
• 各类型市场明细
• 流通管道市场明细
• 各地区市场明细

第4章 神经原因性膀胱炎市场动态

• 影响市场的要素
  • 促进因素
  • 阻碍因素
  • 市场机会
  • 影响分析

第5章 神经原因性膀胱炎市场-产业分析

• 波特的五力分析
• 供应链分析
• 价格分析
• 法规分析
• 未满足需求

第6章 神经原因性膀胱炎市场-COVID-19分析

第7章 神经原因性膀胱炎市场-各药物类型

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)、各药物类型
• 市场魅力指数，各药物类型
  • 抗胆碱药
  • 磺胺类药物
  • Azole和Amphotericin B
  • 四环霉素
  • 硝基馅饼
  • Aminoglycosides系抗生素
  • 头孢菌素
  • 奎诺酮
  • 与青霉素并用

第8章 神经原因性膀胱炎市场-各类型

• 简介
• 市场规模分析，及与前一年同期比较成长分析(%)、各类型
• 市场魅力指数，各类型
  • 过活动
  • 低活动

第9章 神经原因性膀胱炎市场-各流通管道

• 简介
  • 市场规模分析，及与前一年同期比较成长分析(%)、各流通管道
  • 市场魅力指数，各流通管道
• 院内药局
  • 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
• 零售药局
• 线上药局
• 其他

第10章 神经原因性膀胱炎市场-各地区

• 简介
  • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)，各地区
  • 市场魅力指数，各地区
• 北美
• 欧洲
• 南美
• 亚太地区
• 中东·非洲

第11章 神经原因性膀胱炎市场-竞争情形

• 主要的发展与策略
• 企业占有率分析
• 产品的基准

第12章 神经原因性膀胱炎市场-企业简介

• Astellas Pharma US, Inc
• Pfizer Inc
• Sumitovant Biopharma, Inc.
• Mylan Inc.
• Xiromed

第13章 神经原因性膀胱炎市场-DataM

Market Overview

The global neurogenic bladder infections market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Neurogenic bladder infections are linked to urinary issues in which people lose bladder control due to spinal cord, brain, and nerve issues, which can lead to diseases such as multiple sclerosis, Parkinson's disease, and others.

Market Dynamics

The factors influencing the global neurogenic bladder infections market are the increasing demand for effective treatment and the growing prevalence of chronic diseases.

The increasing demand for an effective treatment is expected to drive the market growth

The urinary system's muscles and nerves work together to hold and release urine at the appropriate times. The bladder sends messages to the spinal cord and brain via nerves. The messages instruct the bladder muscles to either tighten or relax. These nerves do not function properly in the neurogenic bladder. Neurogenic bladder dysfunction, which affects more than 90% of people with spinal cord injuries, is very common. Neurogenic bladder dysfunction affects approximately 95% of people with spina bifida. People with multiple sclerosis are also affected in 50 percent to 80 percent of cases. Neurogenic bladder is a condition that affects people who have had a stroke, Parkinson's disease, or a variety of other nervous system disorders. Neurogenic bladder can be caused by conditions that damage nerves, such as advanced diabetes. Medications may aid in the management of symptoms. Overactive bladder medications such as oxybutynin, tolterodine, solifenacin, and mirabegron relax the bladder. Bladder muscle injections, such as Botulinum toxin injections, relax the bladder. GABA supplements and anti-epileptic drugs are examples of medications that can affect the nervous system. Moreover, the primary goal of NGB treatment is to protect the upper gastrointestinal tract from damage. The second treatment goal is to keep the patient's urinary continence while maintaining their quality of life.

The side effects associated with drugs are expected to hamper the market growth

As part of a comprehensive bladder management program, many different drugs are used to treat neurogenic bladder dysfunction. Though they were originally developed to treat depression, their significant adverse side effect profiles have pushed them to the back of the line for that indication. Sedation, orthostasis, and cardiac conduction blocks are serious side effects of tricyclic antidepressants; these drugs should be cautioned in older people with neurogenic bladder dysfunction. In the case of pregnancy, tricyclics should be avoided. As an off-label (non-FDA approved) indication, the anticholinergic side effects of this class of drugs have been used to reduce bladder detrusor tone in neurogenic bladder dysfunction. Anticholinergic drugs work by blocking the action of acetylcholine, a chemical messenger that sends signals to the brain that cause abnormal bladder contractions in people with overactive bladder. Anticholinergics most common side effects are dry mouth and constipation. The immediate-release versions, which are usually taken multiple times a day, may cause fewer side effects than the extended-release versions, which are taken once a day.

COVID-19 Impact BAnalBysis

Due to the unprecedented increase in coronavirus-infected patients, access to other primary care services was hampered, and non-COVID-19-related diagnoses such as urinary tract infection dropped significantly. In 2020, the weekly rate of UTI diagnosis decreased slightly, possibly slowing the industry's growth in recent months. A significant decrease in urinary tract infection (UTI) diagnoses due to the COVID-19 pandemic, according to a study published in the ADIAN Journal in December 2020, is cause for concern. The pandemic drastically altered primary care when people infected with COVID-19 became infected with SARS-CoV-2. As a result, fewer patients sought primary care services and fewer diagnoses, such as UTIs. In England, the weekly rate of UTI diagnosis per 100,000 population fell from an average of 30-35 to less than 10 between March 30 and April 24, 2020. Hence, with the decline in diagnosis of UTI during COVID-19 is expected to hamper the global neurogenic bladder infections market.

Segment Analysis

The anticholinergic segment is expected to dominate the market growth in the forecast period

For decades, oral antimuscarinic (anticholinergic) medications have been a mainstay of medical therapy for NGB in adults and children with SCI, MS, or spina bifida. Among international guidelines, they are the most commonly cited treatment for NGB. Muscarinic receptor antagonists have long been thought to work by binding to receptors on the detrusor muscle, preventing parasympathetic nerves from releasing acetylcholine. These receptors can now be found on both the detrusor and the mucosa, and newer pharmacotherapeutic agents have been shown to bind to both sites.

Antimuscarinic therapy in NGB is supported by a large body of basic science evidence. M1-5 muscarinic receptor subtypes exist in humans, but only M2 and M3 subtypes exist in the bladder. The density of muscarinic receptors and the sensitivity of the bladder to muscarinic agents is highest in the dome and decreases towards the base of the bladder, allowing for efficient bladder emptying. Oxybutynin has been used to treat NGB for a long time. It is a commonly used drug in children with NGB. It is safe and effective in this population regardless of the formulation (syrup, tablet, extended-release tablets, transdermal). Oxybutynin is an antimuscarinic, spasmolytic, and weak local anaesthetic tertiary amine metabolized by the liver.

Geographical Analysis

North America region is expected to hold the largest market share in the global neurogenic bladder infections market

The growing prevalence of UTIs and better healthcare facilities in this region are expected to drive market growth. During a routine checkup for a UTI, a woman was infected by E. coli that was resistant to the last-resort antibiotic, Colistin, according to an article published in the Infectious Diseases Society of America in November 2020 by Pranita D. Tamma. The discovery of Colistin-resistant bacteria was regarded as a significant problem. In addition, the CDC developed guidelines for preventing catheter-associated UTIs and other healthcare-associated infections in the United States in collaboration with other organizations. Furthermore, the Queensland Pediatric Factsheet 2019 estimated that one in every ten girls and one in every fifty boys would have a urinary tract infection by the age of seven. Infections are more common in boys under one year, but infections are more common in older children. A variety of neurologic conditions can cause NGB dysfunction. In the United States, NGB has been found in 40 percent to 90 percent of patients.

Competitive Landscape

The global neurogenic bladder infections market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Pfizer Inc, Sumitovant Biopharma, Mylan Inc., Astellas Pharma US, Inc, Xiromed

Astellas Pharma US, Inc

Overview: Astellas Pharma US, Inc. is a subsidiary of Astellas Pharma Inc., based in Tokyo, with headquarters in Northbrook, Illinois. Astellas is a pharmaceutical company. It was founded in 2005.

Product Portfolio: Myrbetriq is an adult prescription medication used to treat overactive bladder (OAB) symptoms such as urgency, frequency, and leakage.

Key Development: On 25th March 2021, The U.S FDA approved Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension), a new indication to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction caused by neurological impairment, in children aged three and up. Myrbetriq is also used to treat overactive bladder in adults.

Why Purchase the Report?

Visualize the composition of the global neurogenic bladder infections market segmentation by drug type, type, and distribution channel, highlighting the key commercial assets and players.

Identify commercial opportunities in global neurogenic bladder infections market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global neurogenic bladder infections market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global neurogenic bladder infections market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Neurogenic Bladder Infections MarketMethodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Neurogenic Bladder Infections Market- Market Definition and Overview

3. Neurogenic Bladder Infections Market- Executive Summary

• 3.1. Market Snippet By Drug Type
• 3.2. Market Snippet By Type
• 3.3. Market Snippet By Distribution Channel
• 3.4. Market Snippet By Region

4. Neurogenic Bladder Infections Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing demand for an effective treatment
  • 4.1.2. Restraints:
    • 4.1.2.1. The side effects associated with drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Neurogenic Bladder Infections Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Neurogenic Bladder Infections Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Neurogenic Bladder Infections Market- By Drug Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
• 7.3. Market Attractiveness Index, By Drug Type
  • 7.3.1. Anticholinergic drugs
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Sulphonamides
  • 7.3.3. Azoles and Amphotericin B
  • 7.3.4. Tetracycline
  • 7.3.5. Nitrofurans
  • 7.3.6. Aminoglycoside Antibiotics
  • 7.3.7. Cephalosporin
  • 7.3.8. Quinolones
  • 7.3.9. Penicillin and Combinations

8. Neurogenic Bladder Infections Market-By Type

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
• 8.3. Market Attractiveness Index, By Type
  • 8.3.1. Overactive
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Underactive

9. Neurogenic Bladder Infections Market- By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies
• 9.5. Other

10. Neurogenic Bladder Infections Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Neurogenic Bladder Infections Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Neurogenic Bladder Infections Market- Company Profiles

• 12.1. Astellas Pharma US, Inc*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Pfizer Inc
• 12.3. Sumitovant Biopharma, Inc.
• 12.4. Mylan Inc.
• 12.5. Xiromed

LIST NOT EXHAUSTIVE

13. Neurogenic Bladder Infections Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us